Biofilms in periprosthetic orthopedic infections

Future Microbiology

Volumn 9, Issue 8, 2014, Pages 987-1007

  McConoughey, Stephen J ^a   Howlin, Rob ^b   Granger, Jeff F ^a   Manring, Maurice M ^a   Calhoun, Jason H ^c   Shirtliff, Mark ^d   Kathju, Sandeep ^e   Stoodley, Paul ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c SPECTRUM HEALTH   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

antibiotic resistance; arthroplasty; biofilm; coating; infection; planktonic; prosthesis; treatment

Indexed keywords

ANTIBIOTIC AGENT; ANTIBIOTIC BONE CEMENT; ANTIMICROBIAL METAL NANOPARTICLE; BIOFILM DISAGGREGATING AGENT; BIOFILM DISPERSAL AGENT; BIOSURFACTANT; METAL NANOPARTICLE; METAL OXIDE NANOPARTICLE; NANOPARTICLE; QS INHIBITOR; UNCLASSIFIED DRUG; VACCINE; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTHROPLASTY; BACTERIAL GROWTH; BIOFILM; DEVICE REMOVAL; DRUG COATING; DRUG DELIVERY SYSTEM; HOST RESISTANCE; HUMAN; INFECTION PREVENTION; MATURATION; MOLECULAR DIAGNOSIS; NONHUMAN; ORTHOPEDICS; PERIPROSTHETIC JOINT INFECTION; PERIPROSTHETIC ORTHOPEDIC INFECTION; REVIEW; TOTAL JOINT ARTHROPLASTY; ANIMAL; BACTERIUM; BACTERIUM ADHERENCE; GROWTH, DEVELOPMENT AND AGING; MICROBIOLOGY; PROSTHESIS-RELATED INFECTIONS; REPLACEMENT ARTHROPLASTY;

ANIMALS; ANTI-BACTERIAL AGENTS; ARTHROPLASTY, REPLACEMENT; BACTERIA; BACTERIAL ADHESION; BIOFILMS; HUMANS; PROSTHESIS-RELATED INFECTIONS;

EID: 84908052579     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.14.64     Document Type: Review

References (148)

1. Vergidis P, Patel R. Novel approaches to the diagnosis, prevention, and treatment of medical device-associated infections. Infect. Dis. Clin. N. Am. 26(1), 173-186 (2012).
2. Hansen EN, Zmistowski B, Parvizi J. Periprosthetic joint infection: what is on the horizon? Int. J. Artifc. Organs 35(10), 935-950 (2012).
3. Peel TN, Buising KL, Choong PF. Diagnosis and management of prosthetic joint infection. Curr. Opin. Infect. Dis. 25(6), 670-676 (2012).
4. Zimmerli W, Moser C. Pathogenesis and treatment concepts of orthopedic bioflm infections. FEMS Immunol. Med. Microbiol. 65(2), 158-168 (2012).
5. Romano CL, Toscano M, Romano D, Drago L. Antibioflm agents and implant-related infections in orthopedics: where are we? J. Chemother. 25(2), 67-80 (2013).
6. Levy PY, Fenollar F. The role of molecular diagnostics in implant-associated bone and joint infection. Clin. Microbiol. Infect. 18 (12), 1168-1175 (2012).
7. Esteban J, Sorli L, Alentorn-Geli E, Puig L, Horcajada JP. Conventional and molecular diagnostic strategies for prosthetic joint infections. Expert Rev. Mol. Diagnost. 14(1), 83-96 (2014).
8. Kurtz S, Ong K, Lau E, Mowat F, Halpern M. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J. Bone Joint Surg. Am. 89(4), 780-785 (2007).
9. Game FL. Osteomyelitis in the diabetic foot: diagnosis and management. Med. Clin. N. Am. 97(5), 947-956 (2013).
10. Choong PF, Dowsey MM, Carr D, Daffy J, Stanley P. Risk factors associated with acute hip prosthetic joint infections and outcome of treatment with a rifampinbased regimen. Acta Orthop. 78(6), 755-765 (2007).
11. Jamsen E, Huhtala H, Puolakka T, Moilanen T. Risk factors for infection after knee arthroplasty. A register-based analysis of 43, 149 cases. J. Bone Joint Surg. Am. 91(1), 38-47 (2009).
12. Peersman G, Laskin R, Davis J, Peterson M. Infection in total knee replacement: a retrospective review of 6489 total knee replacements. Clin. Orthoped. Relat. Res. 392, 15-23 (2001).
13. Phillips JE, Crane T P, Noy M, Elliott TS, Grimer RJ. The incidence of deep prosthetic infections in a specialist orthopedic hospital: a 15-year prospective survey. J. Bone Joint Surg. Br. 88(7), 943-948 (2006).
14. Pulido L, Ghanem E, Joshi A, Purtill JJ, Parvizi J. Periprosthetic joint infection: the incidence, timing, and predisposing factors. Clin. Orthoped. Relat. Res. 466 (7), 1710-1715 (2008).
15. Greene LR. Guide to the elimination of orthopedic surgery surgical site infections: an executive summary of the Association for Professionals in Infection Control and Epidemiology elimination guide. Am. J. Infect. Control 40(4), 384-386 (2012).
16. Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-joint infections. N. Engl. J. Med. 351(16), 1645-1654 (2004).
17. Parvizi J, Gehrke T, Chen AF. Proceedings of the international consensus on periprosthetic joint infection. Bone Joint J. 95-B(11), 1450-1452 (2013).
18. Willenegger H, Roth B. [Treatment tactics and late results in early infection following osteosynthesis]. Unfallchirurgie 12(5), 241-246 (1986).
19. Pandey R, Berendt AR, Athanasou NA. Histological and microbiological fndings in non-infected and infected revision arthroplasty tissues. The OSIRIS Collaborative Study Group. Oxford Skeletal Infection Research and Intervention Service. Arch. Orthop. Trauma Surg. 120(10), 570-574 (2000).
20. Achermann Y, Vogt M, Leunig M, Wust J, Trampuz A. Improved diagnosis of periprosthetic joint infection by multiplex PCR of sonication fuid from removed implants. J. Clin. Microbiol. 48(4), 1208-1214 (2010).
21. Sendi P, Rohrbach M, Graber P, Frei R, Ochsner PE, Zimmerli W. Staphylococcus aureus small colony variants in prosthetic joint infection. Clin. Infect. Dis. 43(8), 961-967 (2006).
22. Von Ohle C, Gieseke A, Nistico L, Decker EM, Debeer D, Stoodley P. Real-time microsensor measurement of local metabolic activities in ex vivo dental bioflms exposed to sucrose and treated with chlorhexidine. Appl. Environ. Microbiol. 76(7), 2326-2334 (2010).
23. Stoodley P, Conti SF, Demeo PJ et al. Characterization of a mixed MRSA/MRSE bioflm in an explanted total ankle arthroplasty. FEMS Immunol. Med. Microbiol. 62(1), 66-74 (2011).
24. Stoodley P, Nistico L, Johnson S et al. Direct demonstration of viable Staphylococcus aureus bioflms in an infected total joint arthroplasty. A case report. J. Bone Joint Surg. Am. 90(8), 1751-1758 (2008).
25. Houry A, Briandet R, Aymerich S, Gohar M. Involvement of motility and fagella in Bacillus cereus bioflm formation. Microbiology 156(Pt 4), 1009-1018 (2010).
26. Vuong C, Voyich JM, Fischer ER et al. Polysaccharide intercellular adhesin (PIA) protects Staphylococcus epidermidis against major components of the human innate immune system. Cell. Microbiol. 6(3), 269-275 (2004).
27. Wood TK, Gonzalez Barrios AF, Herzberg M, Lee J. Motility infuences bioflm architecture in Escherichia coli. Appl. Microbiol. Biotechnol. 72(2), 361-367 (2006).
28. Hoiby N, Ciofu O, Johansen HK et al. The clinical impact of bacterial bioflms. Int. J. Oral Sci. 3(2), 55-65 (2011).
29. Papayannopoulos V, Zychlinsky A. NETs: a new strategy for using old weapons. Trends Immunol. 30(11), 513-521 (2009).
30. Rice KC, Mann EE, Endres JL et al. The cidA murein hydrolase regulator contributes to DNA release and bioflm development in Staphylococcus aureus. Proc. Natl Acad. Sci. USA 104(19), 8113-8118 (2007).
31. Gloag ES, Turnbull L, Huang A et al. Self-organization of bacterial bioflms is facilitated by extracellular DNA. Proc. Natl Acad. Sci. USA 110(28), 11541-11546 (2013).
32. Goodman SD, Obergfell KP, Jurcisek JA et al. Bioflms can be dispersed by focusing the immune system on a common family of bacterial nucleoid-associated proteins. Mucosal Immunol. 4(6), 625-637 (2011).
33. Novick RP, Ross HF, Projan SJ, Kornblum J, Kreiswirth B, Moghazeh S. Synthesis of staphylococcal virulence factors is controlled by a regulatory RNA molecule. EMBO J. 12(10), 3967-3975 (1993).
34. Lina G, Jarraud S, Ji G et al. Transmembrane topology and histidine protein kinase activity of AgrC, the agr signal receptor in Staphylococcus aureus. Mol. Microbiol. 28(3), 655-662 (1998).
35. Boles BR, Horswill AR. Agr-mediated dispersal of Staphylococcus aureus bioflms. PLoS Pathog. 4(4), e1000052 (2008).
36. Otto M. Staphylococcus epidermidis-the 'accidental' pathogen. Nat. Rev. Microbiol. 7(8), 555-567 (2009).
37. Galloway WR, Hodgkinson JT, Bowden S, Welch M, Spring DR. Applications of small molecule activators and inhibitors of quorum sensing in Gram-negative bacteria. Trends Microbiol. 20(9), 449-458 (2012).
38. Wood TK, Knabel SJ, Kwan BW. Bacterial persister cell formation and dormancy. Appl. Environ. Microbiol. 79(23), 7116-7121 (2013).
39. Barraud N, Schleheck D, Klebensberger J et al. Nitric oxide signaling in Pseudomonas aeruginosa bioflms mediates phosphodiesterase activity, decreased cyclic di-GMP levels, and enhanced dispersal. J. Bacteriol. 191(23), 7333-7342 (2009).
40. Amari DT, Marques CN, Davies DG. The putative enoyl-coenzyme A hydratase DspI is required for production of the Pseudomonas aeruginosa bioflm dispersion autoinducer cis-2-decenoic acid. J. Bacteriol. 195(20), 4600-4610 (2013).
41. Huang C T, Yu FP, Mcfeters GA, Stewart PS. Nonuniform spatial patterns of respiratory activity within bioflms during disinfection. Appl. Environ. Microbiol. 61(6), 2252-2256 (1995).
42. Hoiby N. Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fbrosis. BMC Med. 9, 32 (2011).
43. Jefferson KK, Goldmann DA, Pier GB. Use of confocal microscopy to analyze the rate of vancomycin penetration through Staphylococcus aureus bioflms. Antimicrob. Agents Chemother. 49(6), 2467-2473 (2005).
44. Anwar H, Costerton JW. Enhanced activity of combination of tobramycin and piperacillin for eradication of sessile bioflm cells of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 34(9), 1666-1671 (1990).
45. Furustrand Tafn U, Majic I, Zalila Belkhodja C et al. Gentamicin improves the activities of daptomycin and vancomycin against Enterococcus faecalis in vitro and in an experimental foreign-body infection model. Antimicrob. Agents Chemother. 55(10), 4821-4827 (2011).
46. Moskowitz SM, Foster JM, Emerson J, Burns JL. Clinically feasible bioflm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fbrosis. J. Clin. Microbiol. 42 (5), 1915-1922 (2004).
47. Costerton JW, Lewandowski Z, Caldwell DE, Korber DR, Lappin-Scott HM. Microbial bioflms. Annu. Rev. Microbiol. 49, 711-745 (1995).
48. Fux CA, Wilson S, Stoodley P. Detachment characteristics and oxacillin resistance of Staphyloccocus aureus bioflm emboli in an in vitro catheter infection model. J. Bacteriol. 186(14), 4486-4491 (2004).
49. Hoiby N, Bjarnsholt T, Givskov M, Molin S, Ciofu O. Antibiotic resistance of bacterial bioflms. Int. J. Antimicrob. Agents 35(4), 322-332 (2010).
50. Ciofu O, Bagge N, Hoiby N. Antibodies against beta-lactamase can improve ceftazidime treatment of lung infection with beta-lactam-resistant Pseudomonas aeruginosa in a rat model of chronic lung infection. APMIS 110(12), 881-891 (2002).
51. Jensen PO, Givskov M, Bjarnsholt T, Moser C. The immune system vs. Pseudomonas aeruginosa bioflms. FEMS Immunol. Med. Microbiol. 59(3), 292-305 (2010).
52. Zimmerli W, Sendi P. Pathogenesis of implant-associated infection: the role of the host. Sem. Immunopathol. 33(3), 295-306 (2011).
53. Leid JG, Shirtliff ME, Costerton J W, Stoodley P. Human leukocytes adhere to, penetrate, and respond to Staphylococcus aureus bioflms. Infect. Immun. 70(11), 6339-6345 (2002).
54. Zimmerli W, Lew PD, Waldvogel FA. Pathogenesis of foreign body infection. Evidence for a local granulocyte defect. J. Clin. Invest. 73 (4), 1191-1200 (1984).
55. Tashiro Y, Nomura N, Nakao R et al. Opr86 is essential for viability and is a potential candidate for a protective antigen against bioflm formation by Pseudomonas aeruginosa. J. Bacteriol. 190(11), 3969-3978 (2008).
56. Zimmerli W, Waldvogel FA, Vaudaux P, Nydegger UE. Pathogenesis of foreign body infection: description and characteristics of an animal model. J. Infect. Dis. 146(4), 487-497 (1982).
57. Elek SD, Conen PE. The virulence of Staphylococcus pyogenes for man; a study of the problems of wound infection. Br. J. Exp. Pathol. 38(6), 573-586 (1957).
58. Lam J, Chan R, Lam K, Costerton J W. Production of mucoid microcolonies by Pseudomonas aeruginosa within infected lungs in cystic fbrosis. Infect. Immun. 28(2), 546-556 (1980).
59. De Beer D, Stoodley P, Lewandowski Z. Measurement of local diffusion coeffcients in bioflms by microinjection and confocal microscopy. Biotechnol. Bioengin. 53(2), 151-158 (1997).
60. Cerca N, Jefferson KK, Oliveira R, Pier GB, Azeredo J. Comparative antibody-mediated phagocytosis of Staphylococcus epidermidis cells grown in a bioflm or in the planktonic state. Infect. Immun. 74(8), 4849-4855 (2006).
61. Hoiby N, Ciofu O, Bjarnsholt T. Pseudomonas aeruginosa bioflms in cystic fbrosis. Future Microbiol. 5(11), 1663-1674 (2010).
62. Benakanakere M, Kinane DF. Innate cellular responses to the periodontal bioflm. Front. Oral Biol. 15, 41-55 (2012).
63. Widmer AF. New developments in diagnosis and treatment of infection in orthopedic implants. Clin. Infect. Dis. 33(Suppl. 2), S94-S106 (2001).
64. Hall-Stoodley L, Hu FZ, Gieseke A et al. Direct detection of bacterial bioflms on the middle-ear mucosa of children with chronic otitis media. JAMA 296(2), 202-211 (2006)
65. Workgroup Convened by the Musculoskeletal Infection Society. New defnition for periprosthetic joint infection. J. Arthroplast. 26 (8), 1136-1138 (2011).
66. Tetreault M W, Wetters NG, Aggarwal VK et al. Should draining wounds and sinuses associated with hip and knee arthroplasties be cultured? J. Arthroplast. 28(8 Suppl.), 133-136 (2013).
67. Tigges S, Stiles RG, Roberson JR. Appearance of septic hip prostheses on plain radiographs. AJR Am. J. Roentgenol. 163(2), 377-380 (1994).
68. Purdue PE, Koulouvaris P, Nestor BJ, Sculco TP. The central role of wear debris in periprosthetic osteolysis. HSS J. 2(2), 102-113 (2006).
69. Levy PY, Fournier PE, Fenollar F, Raoult D. Systematic PCR detection in culture-negative osteoarticular infections. Am. J. Med. 126(12), 1143.e25-e33 (2013).
70. Palmer MP, Altman DT, Altman GT et al. Can we trust intraoperative culture results in nonunions? J. Orthped. Trauma 28(7), 384-390 (2014).
71. Guembe M, Marin M, Martin-Rabadan P et al. Use of universal 16S rRNA gene PCR as a diagnostic tool for venous access port-related bloodstream infections. J. Clin. Microbiol. 51(3), 799-804 (2013).
72. Jacovides CL, Kreft R, Adeli B, Hozack B, Ehrlich GD, Parvizi J. Successful identifcation of pathogens by polymerase chain reaction (PCR)-based electron spray ionization time-of-fight mass spectrometry (ESI-TOF-MS) in culture-negative periprosthetic joint infection. J. Bone Joint Surg. Am. 94(24), 2247-2254 (2012).
73. Trampuz A, Steckelberg JM, Osmon DR et al. Advances in the laboratory diagnosis of prosthetic joint infection. Rev. Med. Microbiol. 14(1), 1-14 (2003).
74. Trampuz A, Piper KE, Jacobson MJet al. Sonication of removed hip and knee prostheses for diagnosis of infection. N. Engl. J. Med 357(7), 654-663 (2007).
75. Sorli L, Puig L, Torres-Claramunt R et al. The relationship between microbiology results in the second of a two-stage exchange procedure using cement spacers and the outcome after revision total joint replacement for infection: the use of sonication to aid bacteriological analysis. J Bone Joint Surg. Br. 94(2), 249-253 (2012).
76. Zaat S, Broekhuizen C, Riool M. Host tissue as a niche for biomaterial-associated infection. Future Microbiol. 8, 1149-1151 (2010).
77. Tunney MM, Patrick S, Curran MD et al. Detection of prosthetic hip infection at revision arthroplasty by immunofuorescence microscopy and PCR amplifcation of the bacterial 16S rRNA gene. J. Clin. Microbiol. 37(10), 3281-3290 (1999).
78. Borens O, Yusuf E, Steinrucken J, Trampuz A. Accurate and early diagnosis of orthopedic device-related infection by microbial heat production and sonication. J. Orthped. Res. 31(11), 1700-1703 (2013).
79. Kathju S, Nistico L, Hall-Stoodley L, Post JC, Ehrlich GD, Stoodley P. Chronic surgical site infection due to suture-associated polymicrobial bioflm. Surg. Infect. (Larchmt) 10 (5), 457-461 (2009).
80. Trampuz A, Osmon DR, Hanssen AD, Steckelberg JM, Patel R. Molecular and antibioflm approaches to prosthetic joint infection. Clin. Orthoped. Relat. Res. 414, 69-88 (2003).
81. Levy PY, Ollivier M, Drancourt M, Raoult D, Argenson JN. Relation between nasal carriage of Staphylococcus aureus and surgical site infection in orthopedic surgery: the role of nasal contamination. A systematic literature review and meta-analysis. Orthoped. Traumatol. Surg. Res. 99(6), 645-651 (2013).
82. Marculescu CE, Osmon DR. Antibiotic prophylaxis in orthopedic prosthetic surgery. Infect. Dis. Clin. N. Am. 19(4), 931-946 (2005).
83. Widmer AF. [Infections and sepsis from intravascular catheters]. Internist (Berl.) 46(6), 643-651 (2005).
84. Cordero J, Munuera L, Folgueira MD. The infuence of the chemical composition and surface of the implant on infection. Injury 27(Suppl. 3), SC34-SC37 (1996).
85. Cordero J, Munuera L, Folgueira MD. Infuence of metal implants on infection. An experimental study in rabbits. J. Bone Joint Surg. Br. 76(5), 717-720 (1994).
86. Deligianni DD, Katsala N, Ladas S, Sotiropoulou D, Amedee J, Missirlis YF. Effect of surface roughness of the titanium alloy Ti-6Al-4V on human bone marrow cell response and on protein adsorption. Biomaterials 22(11), 1241-1251 (2001).
87. Gomez-Barrena E, Esteban J, Medel F et al. Bacterial adherence to separated modular components in joint prosthesis: a clinical study. J. Orthped. Res. 30 (10), 1634-1639 (2012).
88. Swartz RD, Messana JM, Boyer CJ, Lunde NM, Weitzel WF, Hartman TL. Successful use of cuffed central venous hemodialysis catheters inserted percutaneously. J. Am. Soc. Nephrol. 4 (9), 1719-1725 (1994).
89. Lund GB, Trerotola SO, Scheel PF Jr et al. Outcome of tunneled hemodialysis catheters placed by radiologists. Radiology 198(2), 467-472 (1996).
90. Marr KA, Sexton DJ, Conlon PJ, Corey GR, Schwab SJ, Kirkland KB. Catheter-related bacteremia and outcome of attempted catheter salvage in patients undergoing hemodialysis. Ann. Intern. Med. 127(4), 275-280 (1997).
91. Saad TF. Bacteremia associated with tunneled, cuffed hemodialysis catheters. Am. J. Kidney Dis. 34 (6), 1114-1124 (1999).
92. Pourchez T, Moriniere P, Fournier A, Pietri J. Use of Permcath (Quinton) catheter in uraemic patients in whom the creation of conventional vascular access for haemodialysis is diffcult. Nephron 53(4), 297-302 (1989).
93. Callaghan JJ, Katz RP, Johnston RC. One-stage revision surgery of the infected hip. A minimum 10-year followup study. Clin. Orthoped. Relat. Res. 369, 139-143 (1999).
94. Hope PG, Kristinsson KG, Norman P, Elson RA. Deep infection of cemented total hip arthroplasties caused by coagulase-negative staphylococci. J. Bone Joint Surg. Br. 71(5), 851-855 (1989)
95. Raut V V, Siney PD, Wroblewski BM. One-stage revision of infected total hip replacements with discharging sinuses. J. Bone Joint Surg. Br. 76(5), 721-724 (1994).
96. Ure KJ, Amstutz HC, Nasser S, Schmalzried TP. Direct-exchange arthroplasty for the treatment of infection after total hip replacement. An average ten-year follow-up. J. Bone Joint Surg. Am. 80(7), 961-968 (1998).
97. Colyer RA, Capello WN. Surgical treatment of the infected hip implant. Two-stage reimplantation with a one-month interval. Clin. Orthoped. Relat. Res. 298, 75-79 (1994).
98. Langlais F. Can we improve the results of revision arthroplasty for infected total hip replacement? J. Bone Joint Surg. Br. 85(5), 637-640 (2003).
99. Windsor RE, Insall JN, Urs WK, Miller DV, Brause BD. Two-stage reimplantation for the salvage of total knee arthroplasty complicated by infection. Further follow-up and refnement of indications. J. Bone Joint Surg. Am. 72(2), 272-278 (1990).
100. Zimmerli W, Ochsner PE. Management of infection associated with prosthetic joints. Infection 31(2), 99-108 (2003).
101. Westrich G, Salvati EA, Brause B. Postoperative infection. In: Revision Total Hip Arthroplasty. Bono JV, McCarthy JC, Thornhill TS et al. (Eds). Springer, NY, USA, 371-390 (1999).
102. Arciola CR, Campoccia D, Speziale P, Montanaro L, Costerton JW. Bioflm formation in Staphylococcus implant infections. A review of molecular mechanisms and implications for bioflm-resistant materials. Biomaterials 33(26), 5967-5982 (2012).
103. Rodrigues LR. Inhibition of bacterial adhesion on medical devices. Adv. Exp. Med. Biol. 715, 351-367 (2011).
104. Bryers JD. Medical bioflms. Biotechnol. Bioengin. 100(1), 1-18 (2008).
105. Hetrick EM, Schoenfsch MH. Reducing implant-related infections: active release strategies. Chem. Soc. Rev. 35(9), 780-789 (2006).
106. Gottenbos B, Grijpma DW, Van Der Mei HC, Feijen J, Busscher HJ. Antimicrobial effects of positively charged surfaces on adhering Gram-positive and Gram-negative bacteria. J. Antimicrob. Chemother. 48(1), 7-13 (2001).
107. Arciola CR, Caramazza R, Pizzoferrato A. In vitro adhesion of Staphylococcus epidermidis on heparin-surface-modifed intraocular lenses. J. Cataract Refract. Surg. 20(2), 158-161 (1994).
108. Arciola CR, Radin L, Alvergna P, Cenni E, Pizzoferrato A. Heparin surface treatment of poly(methylmethacrylate) alters adhesion of a Staphylococcus aureus strain: utility of bacterial fatty acid analysis. Biomaterials 14 (15), 1161-1164 (1993).
109. Nagaoka S, Kawakami H. Inhibition of bacterial adhesion and bioflm formation by a heparinized hydrophilic polymer. ASAIO J. 41(3), M365-M368 (1995).
110. Ruggieri MR, Hanno PM, Levin RM. Reduction of bacterial adherence to catheter surface with heparin. J. Urol. 138(2), 423-426 (1987).
111. Clement JL, Jarrett PS. Antibacterial silver. Met. Based Drugs 1(5-6), 467-482 (1994).
112. Flemming CA, Ferris FG, Beveridge TJ, Bailey GW. Remobilization of toxic heavy metals adsorbed to bacterial wall-clay composites. Appl. Environ. Microbiol. 56 (10), 3191-3203 (1990).
113. Liau SY, Read DC, Pugh WJ, Furr JR, Russell AD. Interaction of silver nitrate with readily identifable groups: relationship to the antibacterial action of silver ions. Lett. Appl. Microbiol. 25(4), 279-283 (1997).
114. Matsumura Y, Yoshikata K, Kunisaki S, Tsuchido T. Mode of bactericidal action of silver zeolite and its comparison with that of silver nitrate. Appl. Environ. Microbiol. 69(7), 4278-4281 (2003).
115. Fayaz AM, Balaji K, Girilal M, Yadav R, Kalaichelvan PT, Venketesan R. Biogenic synthesis of silver nanoparticles and their synergistic effect with antibiotics: a study against Gram-positive and Gram-negative bacteria. Nanomedicine 6(1), 103-109 (2010).
116. Roe D, Karandikar B, Bonn-Savage N, Gibbins B, Roullet JB. Antimicrobial surface functionalization of plastic catheters by silver nanoparticles. J. Antimicrob. Chemother. 61(4), 869-876 (2008).
117. Secinti KD, Ozalp H, Attar A, Sargon MF. Nanoparticle silver ion coatings inhibit bioflm formation on titanium implants. J. Clin. Neurosci. 18(3), 391-395 (2011).
118. Huang Z, Zheng X, Yan D et al. Toxicological effect of ZnO nanoparticles based on bacteria. Langmuir 24(8), 4140-4144 (2008).
119. Xie Y, He Y, Irwin PL, Jin T, Shi X. Antibacterial activity and mechanism of action of zinc oxide nanoparticles against Campylobacter jejuni. Appl. Environ. Microbiol. 77(7), 2325-2331 (2011).
120. Raghupathi KR, Koodali RT, Manna AC. Size-dependent bacterial growth inhibition and mechanism of antibacterial activity of zinc oxide nanoparticles. Langmuir 27(7), 4020-4028 (2011).
121. Seil JT, Webster TJ. Reduced Staphylococcus aureus proliferation and bioflm formation on zinc oxide nanoparticle PVC composite surfaces. Acta Biomater. 7(6), 2579-2584 (2011).
122. Aydin Sevinc B, Hanley L. Antibacterial activity of dental composites containing zinc oxide nanoparticles. J. Biomed. Mater. Res. B Appl. Biomater. 94(1), 22-31 (2010).
123. Kim JS, Adamcakova-Dodd A, O'Shaughnessy PT, Grassian VH, Thorne PS. Effects of copper nanoparticle exposure on host defense in a murine pulmonary infection model. Part. Fibre Toxicol. 8, 29 (2011).
124. Kruszewski KM, Nistico L, Longwell MJ et al. Reducing Staphylococcus aureus bioflm formation on stainless steel 316L using functionalized self-assembled monolayers. Materials Sci. engineering. C, Mat. Biol. Appl. 33(4), 2059-2069 (2013).
125. Stewart S, Barr S, Engiles J et al. Vancomycin-modifed implant surface inhibits bioflm formation and supports bone-healing in an infected osteotomy model in sheep: a proof-of-concept study. J. Bone Joint Surg. Am. 94 (15), 1406-1415 (2012).
126. Patti BN, Lindeque BG. Antibiotic-loaded acrylic bone cement in the revision of septic arthroplasty: where's the evidence? Orthopedics 34(3), 210 (2011).
127. Dunbar MJ. Antibiotic bone cements: their use in routine primary total joint arthroplasty is justifed. Orthopedics 32(9), pii: orthosupersite. com/view.asp?rID=42849 (2009).
128. Lee GH, Khoury JG, Bell JE, Buckwalter JA. Adverse reactions to OsteoSet bone graft substitute, the incidence in a consecutive series. Iowa Orthped. J. 22, 35-38 (2002).
129. Mousset B, Benoit MA, Delloye C, Bouillet R, Gillard J. Biodegradable implants for potential use in bone infection. An in vitro study of antibiotic-loaded calcium sulphate. Int. Orthoped. 19 (3), 157-161 (1995).
130. Kanellakopoulou K, Galanopoulos I, Soranoglou V et al. Treatment of experimental osteomyelitis caused by methicillin-resistant Staphylococcus aureus with a synthetic carrier of calcium sulphate (Stimulan) releasing moxifoxacin. Int. J. Antimicrob. Agents 33(4), 354-359 (2009).
131. Roberts R, McConoughey SJ, Calhoun JH. Size and composition of synthetic calcium sulfate beads infuence dissolution and elution rates in vitro. J. Biomed. Mater. Res. B Appl. Biomater. 102(4), 667-673 (2013).
132. Kluin OS, Van Der Mei HC, Busscher HJ, Neut D. Biodegradable vs non-biodegradable antibiotic delivery devices in the treatment of osteomyelitis. Expert Opin. Drug Deliv. 10 (3), 341-351 (2013).
133. Josefsson E, Hartford O, O'Brien L, Patti JM, Foster T. Protection against experimental Staphylococcus aureus arthritis by vaccination with clumping factor A, a novel virulence determinant. J. Infect. Dis. 184 (12), 1572-1580 (2001).
134. Kuklin NA, Clark DJ, Secore S et al. A novel Staphylococcus aureus vaccine: iron surface determinant B induces rapid antibody responses in rhesus macaques and specifc increased survival in a murine S. aureus sepsis model. Infect. Immun. 74(4), 2215-2223 (2006).
135. Brady RA, O'May GA, Leid JG, Prior ML, Costerton JW, Shirtliff ME. Resolution of Staphylococcus aureus bioflm infection using vaccination and antibiotic treatment. Infect. Immun. 79(4), 1797-1803 (2011).
136. Peterson BW, Van Der Mei HC, Sjollema J, Busscher HJ, Sharma PK. A distinguishable role of eDNA in the viscoelastic relaxation of bioflms. MBio 4(5), e00497-13 (2013).
137. Kiedrowski MR, Kavanaugh JS, Malone CL et al. Nuclease modulates bioflm formation in community-associated methicillin-resistant Staphylococcus aureus. PLoS ONE 6(11), e26714 (2011).
138. Kaplan JB. Therapeutic potential of bioflm-dispersing enzymes. Int. J. Artifc. Organs 32(9), 545-554 (2009).
139. Hall-Stoodley L, Nistico L, Sambanthamoorthy K et al. Characterization of bioflm matrix, degradation by DNase treatment and evidence of capsule downregulation in Streptococcus pneumoniae clinical isolates. BMC Microbiol. 8, 173 (2008).
140. Tetz GV, Artemenko NK, Tetz V V. Effect of DNase and antibiotics on bioflm characteristics. Antimicrob. Agents Chemother. 53(3), 1204-1209 (2009)
141. Tetz V V, Tetz GV. Effect of extracellular DNA destruction by DNase I on characteristics of forming bioflms. DNA Cell Biol. 29(8), 399-405 (2010).
142. Darouiche RO, Mansouri MD, Gawande PV, Madhyastha S. Antimicrobial and antibioflm effcacy of triclosan and DispersinB combination. J. Antimicrob. Chemother. 64(1), 88-93 (2009).
143. Donelli G, Francolini I, Romoli D et al. Synergistic activity of dispersin B and cefamandole nafate in inhibition of staphylococcal bioflm growth on polyurethanes. Antimicrob. Agents Chemother. 51(8), 2733-2740 (2007).
144. Hentzer M, Wu H, Andersen JB et al. Attenuation of Pseudomonas aeruginosa virulence by quorum sensing inhibitors. EMBO J. 22 (15), 3803-3815 (2003).
145. Wu H, Song Z, Hentzer M et al. Synthetic furanones inhibit quorum-sensing and enhance bacterial clearance in Pseudomonas aeruginosa lung infection in mice. J. Antimicrob. Chemother. 53(6), 1054-1061 (2004).
146. Papaioannou E, Wahjudi M, Nadal-Jimenez P, Koch G, Setroikromo R, Quax WJ. Quorum-quenching acylase reduces the virulence of Pseudomonas aeruginosa in a Caenorhabditis elegans infection model. Antimicrob. Agents Chemother. 53(11), 4891-4897 (2009).
147. Jennings JA, Courtney HS, Haggard WO. Cis-2-decenoic acid inhibits S. aureus growth and bioflm in vitro: a pilot study. Clin. Orthoped. Relat. Res. 470(10), 2663-2670 (2012).
148. Conlon BP, Nakayasu ES, Fleck LE et al. Activated ClpP kills persisters and eradicates a chronic bioflm infection. Nature 503 (7476), 365-370 (2013).